BENIGN HEMATOLOGY PROGRAM

Hemoglobinopathies Clinical Research

 

1- Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018 Jan 13;391(10116):155-167. doi: 10.1016/S0140-6736(17)31822-6. Epub 2017 Jul 31. PMID: 28774421.

2- Taher AT, Musallam KM, Cappellini MD. β-Thalassemias. N Engl J Med. 2021 Feb 25;384(8):727-743. doi: 10.1056/NEJMra2021838. PMID: 33626255

3- Halawi R, Moukhadder H, Taher A. Anemia in the elderly: a consequence of aging? Expert Rev Hematol. 2017 Apr;10(4):327-335. doi: 10.1080/17474086.2017.1285695. Epub 2017 Feb 2. PMID: 28110585.

4- Musallam KM, Bou-Fakhredin R, Cappellini MD, Taher AT. 2021 update on clinical trials in β-thalassemia. Am J Hematol. 2021 Nov 1;96(11):1518-1531. doi: 10.1002/ajh.26316. Epub 2021 Aug 18. PMID: 34347889.

5- Gupta R, Musallam KM, Taher AT, Rivella S. Ineffective Erythropoiesis: Anemia and Iron Overload. Hematol Oncol Clin North Am. 2018 Apr;32(2):213-221. doi: 10.1016/j.hoc.2017.11.009. Epub 2017 Dec 29. PMID: 29458727; PMCID: PMC5824437.

6- Motta I, Bou-Fakhredin R, Taher AT, Cappellini MD. Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation. Drugs. 2020 Jul;80(11):1053-1063. doi: 10.1007/s40265-020-01341-9. PMID: 32557398; PMCID: PMC7299245.

7- Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):265-271. doi: 10.1182/asheducation-2017.1.265. PMID: 29222265; PMCID: PMC6142532.

8- Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, Voskaridou E, Liew HK, Pazgal-Kobrowski I, Forni GL, Perrotta S, Khelif A, Lal A, Kattamis A, Vlachaki E, Origa R, Aydinok Y, Bejaoui M, Ho PJ, Chew LP, Bee PC, Lim SM, Lu MY, Tantiworawit A, Ganeva P, Gercheva L, Shah F, Neufeld EJ, Thompson A, Laadem A, Shetty JK, Zou J, Zhang J, Miteva D, Zinger T, Linde PG, Sherman ML, Hermine O, Porter J, Piga A; BELIEVE Investigators. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia. N Engl J Med. 2020 Mar 26;382(13):1219-1231. doi: 10.1056/NEJMoa1910182. PMID: 32212518.

9- Karimi M, Haghpanah S, Taher AT, Cappellini MD. β-Thalassemia: New Therapeutic Modalities, Genetics, Complications, and Quality of Life. Anemia. 2012;2012:902067. doi: 10.1155/2012/902067. Epub 2012 Sep 18. PMID: 23019522; PMCID: PMC3457590.

10- Cappellini MD, Taher AT. The use of luspatercept for thalassemia in adults. Blood Adv. 2021 Jan 12;5(1):326-333. doi: 10.1182/bloodadvances.2020002725. PMID: 33570654; PMCID: PMC7805339.

11- Taher AT. Thalassemia. Hematol Oncol Clin North Am. 2018 Apr;32(2):xv-xvi. doi: 10.1016/j.hoc.2017.12.003. Epub 2017 Dec 30. PMID: 29458738.

12- Taher AT, Musallam KM, Cappellini MD. β-Thalassemias. Reply. N Engl J Med. 2021 Jun 3;384(22):2166. doi: 10.1056/NEJMc2105064. PMID: 34077657.

13- Guerra A, Musallam KM, Taher AT, Rivella S. Emerging Therapies. Hematol Oncol Clin North Am. 2018 Apr;32(2):343-352. doi: 10.1016/j.hoc.2017.11.002. Epub 2017 Dec 15. Erratum in: Hematol Oncol Clin North Am. 2018 Jun;32(3):xiii. PMID: 29458736; PMCID: PMC5823282.

14- Taher AT, Otrock ZK, Uthman I, Cappellini MD. Thalassemia and hypercoagulability. Blood Rev. 2008 Sep;22(5):283-92. doi: 10.1016/j.blre.2008.04.001. Epub 2008 Jun 3. PMID: 18511163.

15- Taher AT, Cappellini MD. Luspatercept for β-thalassemia: beyond red blood cell transfusions. Expert Opin Biol Ther. 2021 Nov;21(11):1363-1371. doi: 10.1080/14712598.2021.1968825. Epub 2021 Aug 23. PMID: 34404288.

16- Marcon A, Motta I, Taher AT, Cappellini MD. Clinical Complications and Their Management. Hematol Oncol Clin North Am. 2018 Apr;32(2):223-236. doi: 10.1016/j.hoc.2017.11.005. Epub 2017 Dec 28. PMID: 29458728.

17- Saliba AN, Taher AT. Morbidities in non-transfusion-dependent thalassemia. Ann N Y Acad Sci. 2016 Mar;1368(1):82-94. doi: 10.1111/nyas.13083. PMID: 27186941.

18- Hodroj MH, Bou-Fakhredin R, Nour-Eldine W, Noureldine HA, Noureldine MHA, Taher AT. Thalassemia and malignancy: An emerging concern? Blood Rev. 2019 Sep;37:100585. doi: 10.1016/j.blre.2019.06.002. Epub 2019 Jun 22. PMID: 31253373.

19- Moukalled NM, Bou-Fakhredin R, Taher AT. Deferasirox: Over a Decade of Experience in Thalassemia. Mediterr J Hematol Infect Dis. 2018 Nov 1;10(1):e2018066. doi: 10.4084/MJHID.2018.066. PMID: 30416698; PMCID: PMC6223547.

20- Cappellini MD, Musallam KM, Poggiali E, Taher AT. Hypercoagulability in non-transfusion-dependent thalassemia. Blood Rev. 2012 Apr;26 Suppl 1:S20-3. doi: 10.1016/S0268-960X(12)70007-3. PMID: 22631037.

21- Porter J, Taher A, Mufarrij A, Gavalas M. Emergency Management of Thalassaemia [Internet]. Eleftheriou A, Angastiniotis M, Telfer P, editors. Nicosia (Cyprus): Thalassaemia International Federation; 2012. PMID: 24672825.

22- Noureldine MHA, Taher AT, Haydar AA, Berjawi A, Khamashta MA, Uthman I. Rheumatological complications of beta-thalassaemia: an overview. Rheumatology (Oxford). 2018 Jan 1;57(1):19-27. doi: 10.1093/rheumatology/kex058. PMID: 28371817.

23- Maakaron JE, Cappellini MD, Taher AT. An update on thalassemia intermedia. J Med Liban. 2013 Jul-Sep;61(3):175-82. doi: 10.12816/0001447. PMID: 24422369.

24- Taher AT, Bou-Fakhredin R, Kattamis A, Viprakasit V, Cappellini MD. Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies. Expert Rev Hematol. 2021 Oct;14(10):897-909. doi: 10.1080/17474086.2021.1977116. Epub 2021 Sep 15. PMID: 34493145.

25- El Rassi F, Cappellini MD, Inati A, Taher A. Beta-thalassemia intermedia: an overview. Pediatr Ann. 2008 May;37(5):322-8. doi: 10.3928/00904481-20080501-06. PMID: 18543543.

26- Sleiman J, Tarhini A, Bou-Fakhredin R, Saliba AN, Cappellini MD, Taher AT. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management. Int J Mol Sci. 2018 Jan 8;19(1):182. doi: 10.3390/ijms19010182. PMID: 29316681; PMCID: PMC5796131.

27- Saliba A, Taher A. Iron overload in transfusion-dependent thalassemia. Hematology. 2015 Jun;20(5):311-2. doi: 10.1179/1024533215Z.000000000365. PMID: 25967377.

28- Taher A, Isma’eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006 Jul-Aug;37(1):12-20. doi: 10.1016/j.bcmd.2006.04.005. Epub 2006 Jun 5. PMID: 16737833.

29- Paul A, Thomson VS, Refat M, Al-Rawahi B, Taher A, Nadar SK. Cardiac involvement in beta-thalassaemia: current treatment strategies. Postgrad Med. 2019 May;131(4):261-267. doi: 10.1080/00325481.2019.1608071. Epub 2019 May 6. PMID: 31002266.

30- Bou-Fakhredin R, Tabbikha R, Daadaa H, Taher AT. Emerging therapies in β-thalassemia: toward a new era in management. Expert Opin Emerg Drugs. 2020 Jun;25(2):113-122. doi: 10.1080/14728214.2020.1752180. Epub 2020 Apr 15. PMID: 32249632.

31- Musallam KM, Taher AT, Rachmilewitz EA. β-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med. 2012 Jul;2(7):a013482. doi: 10.1101/cshperspect.a013482. PMID: 22762026; PMCID: PMC3385943.

32- Haidar R, Mhaidli H, Musallam KM, Taher AT. The spine in β-thalassemia syndromes. Spine (Phila Pa 1976). 2012 Feb 15;37(4):334-9. doi: 10.1097/BRS.0b013e31821bd095. PMID: 21494197.

33- Cappellini MD, Poggiali E, Taher AT, Musallam KM. Hypercoagulability in β-thalassemia: a status quo. Expert Rev Hematol. 2012 Oct;5(5):505-11; quiz 512. doi: 10.1586/ehm.12.42. PMID: 23146054.

34- Karimi M, Cohan N, De Sanctis V, Mallat NS, Taher A. Guidelines for diagnosis and management of Beta-thalassemia intermedia. Pediatr Hematol Oncol. 2014 Oct;31(7):583-96. doi: 10.3109/08880018.2014.937884. PMID: 25247665.

35- Haddad A, Tyan P, Radwan A, Mallat N, Taher A. β-Thalassemia Intermedia: A Bird’s-Eye View. Turk J Haematol. 2014 Mar;31(1):5-16. doi: 10.4274/Tjh.2014.0032. Epub 2014 Mar 5. PMID: 24764724; PMCID: PMC3996637.

36- Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of β thalassaemia intermedia. Br J Haematol. 2011 Mar;152(5):512-23. doi: 10.1111/j.1365-2141.2010.08486.x. Epub 2011 Jan 20. PMID: 21250971.

37- Musallam KM, Taher AT. Thrombosis in thalassemia: why are we so concerned? Hemoglobin. 2011;35(5-6):503-10. doi: 10.3109/03630269.2011.605499. Epub 2011 Sep 12. PMID: 21910599.

38- Cappellini MD, Motta I, Musallam KM, Taher AT. Redefining thalassemia as a hypercoagulable state. Ann N Y Acad Sci. 2010 Aug;1202:231-6. doi: 10.1111/j.1749-6632.2010.05548.x. PMID: 20712798.

39- Iolascon A, De Franceschi L, Muckenthaler M, Taher A, Rees D, de Montalembert M, Rivella S, Eleftheriou A, Cappellini MD. EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update. Hemasphere. 2019 Jun 4;3(3):e208. doi: 10.1097/HS9.0000000000000208. PMID: 31723835; PMCID: PMC6746021.

40- Taher AT, Temraz S, Cappellini MD. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia. Expert Rev Hematol. 2013 Oct;6(5):495-509. doi: 10.1586/17474086.2013.827411. Epub 2013 Oct 2. PMID: 24083402.

41- Mallat NS, Mallat SG, Musallam KM, Taher AT. Potential mechanisms for renal damage in beta-thalassemia. J Nephrol. 2013 Sep-Oct;26(5):821-8. doi: 10.5301/jn.5000253. Epub 2013 Mar 6. PMID: 23475461.

42- Taher AT, Musallam KM, Inati A. The hypercoagulable state in thalassemia intermedia. Hemoglobin. 2009;33 Suppl 1:S160-9. doi: 10.3109/03630260903351619. Erratum in: Hemoglobin. 2010;34(1):121-2. PMID: 20001621.

43- Bou-Fakhredin R, Bazarbachi AH, Chaya B, Sleiman J, Cappellini MD, Taher AT. Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia. Int J Mol Sci. 2017 Dec 20;18(12):2778. doi: 10.3390/ijms18122778. PMID: 29261151; PMCID: PMC5751376.

44- Taher AT, Viprakasit V, Musallam KM, Cappellini MD. Treating iron overload in patients with non-transfusion-dependent thalassemia. Am J Hematol. 2013 May;88(5):409-15. doi: 10.1002/ajh.23405. Epub 2013 Mar 8. PMID: 23475638; PMCID: PMC3652024.

45- Saliba AN, Atoui A, Labban M, Hamade H, Bou-Fakhredin R, Mufarrij A, Taher AT. Thalassemia in the emergency department: special considerations for a rare disease. Ann Hematol. 2020 Sep;99(9):1967-1977. doi: 10.1007/s00277-020-04164-6. Epub 2020 Jul 3. PMID: 32621178; PMCID: PMC7333588.

46- Bou-Fakhredin R, Daadaa H, Koussa S, Abou Nasr T, Noun P, Taher AT. SARS-CoV-2 infection in patients with β-thalassemia: Experience from Lebanon. Am J Hematol. 2021 Aug 1;96(8):E285-E288. doi: 10.1002/ajh.26211. Epub 2021 May 13. PMID: 33914955; PMCID: PMC8212121.

47- Musallam KM, Rivella S, Taher AT. Management of non-transfusion-dependent β-thalassemia (NTDT): The next 5 years. Am J Hematol. 2021 Mar 1;96(3):E57-E59. doi: 10.1002/ajh.26055. Epub 2020 Dec 9. PMID: 33219704.

48- Taher AT, Cappellini MD. Management of non-transfusion-dependent thalassemia: a practical guide. Drugs. 2014 Oct;74(15):1719-29. doi: 10.1007/s40265-014-0299-0. PMID: 25255924.

49- Musallam KM, Cappellini MD, Viprakasit V, Kattamis A, Rivella S, Taher AT. Revisiting the non-transfusion-dependent (NTDT) vs. transfusion-dependent (TDT) thalassemia classification 10 years later. Am J Hematol. 2021 Feb 1;96(2):E54-E56. doi: 10.1002/ajh.26056. Epub 2020 Dec 9. PMID: 33219703.

50- Taher AT, Musallam KM, Karimi M, Cappellini MD. Contemporary approaches to treatment of beta-thalassemia intermedia. Blood Rev. 2012 Apr;26 Suppl 1:S24-7. doi: 10.1016/S0268-960X(12)70008-5. PMID: 22631038.

51- Iolascon A, Andolfo I, Russo R, Barcellini W, Fermo E, Toldi G, Ghirardello S, Rees D, Van Wijk R, Kattamis A, Gallagher PG, Roy N, Taher A, Mohty R, Kulozik A, De Franceschi L, Gambale A, De Montalembert M, Forni GL, Harteveld CL, Prchal J, Bianchi P. Summary of Joint European Hematology Association (EHA) and EuroBloodNet Recommendations on Diagnosis and Treatment of Methemoglobinemia. Hemasphere. 2021 Nov 17;5(12):e660. doi: 10.1097/HS9.0000000000000660. PMID: 34805766; PMCID: PMC8598222.

52- Cappellini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Guidelines for the Clinical Management of Thalassaemia [Internet]. 2nd Revised ed. Nicosia (CY): Thalassaemia International Federation; 2008. PMID: 24308075.

53- Taher AT, Musallam KM, Inati A. Iron overload: consequences, assessment, and monitoring. Hemoglobin. 2009;33 Suppl 1:S46-57. doi: 10.3109/03630260903346676. PMID: 20001632.

54- Taher AT, Cappellini MD. How I manage medical complications of β-thalassemia in adults. Blood. 2018 Oct 25;132(17):1781-1791. doi: 10.1182/blood-2018-06-818187. Epub 2018 Sep 11. PMID: 30206117.

55- Musallam KM, Cappellini MD, Taher AT. Variations in hemoglobin level and morbidity burden in non-transfusion-dependent β-thalassemia. Ann Hematol. 2021 Jul;100(7):1903-1905. doi: 10.1007/s00277-021-04456-5. Epub 2021 Feb 11. PMID: 33575946.

56- Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev. 2012 Apr;26 Suppl 1:S16-9. doi: 10.1016/S0268-960X(12)70006-1. PMID: 22631036.

57- Halawi R, Cappellini MD, Taher A. A higher prevalence of hematologic malignancies in patients with thalassemia: Background and culprits. Am J Hematol. 2017 May;92(5):414-416. doi: 10.1002/ajh.24682. Epub 2017 Mar 10. PMID: 28195443.

58- Musallam KM, Cappellini MD, Taher AT. Iron overload in β-thalassemia intermedia: an emerging concern. Curr Opin Hematol. 2013 May;20(3):187-92. doi: 10.1097/MOH.0b013e32835f5a5c. PMID: 23426199.

59- Amid A, Saliba AN, Taher AT, Klaassen RJ. Thalassaemia in children: from quality of care to quality of life. Arch Dis Child. 2015 Nov;100(11):1051-7. doi: 10.1136/archdischild-2014-308112. Epub 2015 Aug 19. PMID: 26289062.

60- Succar J, Musallam KM, Taher AT. Thalassemia and venous thromboembolism. Mediterr J Hematol Infect Dis. 2011;3(1):e2011025. doi: 10.4084/MJHID.2011.025. Epub 2011 May 25. PMID: 21713079; PMCID: PMC3113280.

61- Abdulhai F, Jaffa MA, Elias J, Zakka P, Hotait M, Bou-Fakhredin R, Arnaout S, Taher AT, Refaat MM. Digital thermography and vascular involvement in β-thalassemia intermedia. Ann Hematol. 2021 Oct;100(10):2471-2477. doi: 10.1007/s00277-021-04588-8. Epub 2021 Jul 8. PMID: 34235558.

62- Tavazzi D, Taher A, Cappellini MD. Red blood cell enzyme disorders: an overview. Pediatr Ann. 2008 May;37(5):303-10. doi: 10.3928/00904481-20080501-08. PMID: 18543541.

63- Tyan PI, Radwan AH, Eid A, Haddad AG, Wehbe D, Taher AT. Novel approach to reactive oxygen species in nontransfusion-dependent thalassemia. Biomed Res Int. 2014;2014:350432. doi: 10.1155/2014/350432. Epub 2014 Jul 9. PMID: 25121095; PMCID: PMC4119900.

64- Taher AT, Cappellini MD, Musallam KM. Development of a thalassemia-related thrombosis risk scoring system. Am J Hematol. 2019 Aug;94(8):E207-E209. doi: 10.1002/ajh.25502. Epub 2019 May 13. PMID: 31056770.

65- Musallam KM, Taher AT, Karimi M, Rachmilewitz EA. Cerebral infarction in β-thalassemia intermedia: breaking the silence. Thromb Res. 2012 Nov;130(5):695-702. doi: 10.1016/j.thromres.2012.07.013. Epub 2012 Aug 3. PMID: 22857801.

66- Cappellini MD, Porter JB, Viprakasit V, Taher AT. A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies? Blood Rev. 2018 Jul;32(4):300-311. doi: 10.1016/j.blre.2018.02.001. Epub 2018 Feb 12. PMID: 29455932.

67- Noun P, Ibrahim A, Hodroj MH, Bou-Fakhredin R, Taher AT. COVID-19 in benign hematology: emerging challenges and special considerations for healthcare professionals. Expert Rev Hematol. 2020 Oct;13(10):1081-1092. doi: 10.1080/17474086.2020.1819785. Epub 2020 Sep 15. PMID: 32931348.

68- Haidar R, Mhaidli H, Taher AT. Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia. Eur Spine J. 2010 Jun;19(6):871-8. doi: 10.1007/s00586-010-1357-2. Epub 2010 Mar 5. PMID: 20204423; PMCID: PMC2899982.

69- Musallam KM, Vitrano A, Meloni A, Pollina SA, Karimi M, El-Beshlawy A, Hajipour M, Di Marco V, Ansari SH, Filosa A, Ricchi P, Ceci A, Daar S, Vlachaki E, Singer ST, Naserullah ZA, Pepe A, Scondotto S, Dardanoni G, Bonifazi F, Sankaran VG, Vichinsky E, Taher AT, Maggio A. Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia. Haematologica. 2021 Sep 1;106(9):2489-2492. doi: 10.3324/haematol.2021.278684. PMID: 33882642; PMCID: PMC8409024.

70- Cappellini MD, Musallam KM, Taher AT. Overview of iron chelation therapy with desferrioxamine and deferiprone. Hemoglobin. 2009;33 Suppl 1:S58-69. doi: 10.3109/03630260903346924. PMID: 20001633.

71- Bewersdorf JP, Taher AT, Zeidan AM. No child with a transfusion-dependent haemoglobinopathy left unchelated: are we there yet? Lancet Haematol. 2020 Jun;7(6):e429-e430. doi: 10.1016/S2352-3026(20)30114-9. PMID: 32470430.

72- Musallam KM, Taher AT. Iron chelation therapy for transfusional iron overload: a swift evolution. Hemoglobin. 2011;35(5-6):565-73. doi: 10.3109/03630269.2011.608228. Epub 2011 Sep 12. PMID: 21910602.

73- Moukhadder HM, Halawi R, Cappellini MD, Taher AT. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review. Cancer. 2017 Mar 1;123(5):751-758. doi: 10.1002/cncr.30462. Epub 2016 Dec 1. PMID: 27911488.

74- Saliba AN, El Rassi F, Taher AT. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia. Expert Rev Hematol. 2016;9(2):151-68. doi: 10.1586/17474086.2016.1126176. Epub 2015 Dec 19. PMID: 26613264.

75- Saliba AN, Harb AR, Taher AT. Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. J Blood Med. 2015 Jun 17;6:197-209. doi: 10.2147/JBM.S72463. PMID: 26124688; PMCID: PMC4476479.

76- Musallam KM, Taher AT, Cappellini MD, Sankaran VG. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood. 2013 Mar 21;121(12):2199-212; quiz 2372. doi: 10.1182/blood-2012-10-408021. Epub 2013 Jan 11. PMID: 23315167.

77- Taher A, Vichinsky E, Musallam K, Cappellini MD, Viprakasit V. Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT) [Internet]. Weatherall D, editor. Nicosia (Cyprus): Thalassaemia International Federation; 2013. PMID: 24672826.

78- Taher AT, Musallam KM, Cappellini MD. Thalassaemia intermedia: an update. Mediterr J Hematol Infect Dis. 2009 Aug 29;1(1):e2009004. doi: 10.4084/MJHID.2009.004. PMID: 21415986; PMCID: PMC3033165.

79- Cappellini MD, Musallam KM, Taher AT. Insight onto the pathophysiology and clinical complications of thalassemia intermedia. Hemoglobin. 2009;33 Suppl 1:S145-59. doi: 10.3109/03630260903351528. PMID: 20001620.

80- Inati A, Chabtini L, Mounayar M, Taher A. Current understanding in the management of sickle cell disease. Hemoglobin. 2009;33 Suppl 1:S107-15. doi: 10.3109/03630260903347682. PMID: 20001613.

81- Inati A, Koussa S, Taher A, Perrine S. Sickle cell disease: new insights into pathophysiology and treatment. Pediatr Ann. 2008 May;37(5):311-21. doi: 10.3928/00904481-20080501-07. PMID: 18543542.

82- Chehal A, Loutfi R, Taher A. Beta-thalassemia intermedia and non-Hodgkin’s lymphoma. Hemoglobin. 2002 Aug;26(3):219-25. doi: 10.1081/hem-120015025. PMID: 12403486.

83- Abi Saad M, Haddad AG, Alam ES, Aoun S, Maatouk P, Ajami N, Khairallah T, Koussa S, Musallam KM, Taher AT. Preventing thalassemia in Lebanon: successes and challenges in a developing country. Hemoglobin. 2014;38(5):308-11. doi: 10.3109/03630269.2014.939279. Epub 2014 Jul 17. PMID: 25030035.

84- Cappellini MD, Porter JB, Musallam KM, Kattamis A, Viprakasit V, Galanello R, Taher AT. Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia. Eur J Intern Med. 2016 Mar;28:91-6. doi: 10.1016/j.ejim.2015.10.003. PMID: 26545830.

85- Porter J, Taher A, Viprakasit V, Kattamis A, Coates TD, Garbowski M, Dürrenberger F, Manolova V, Richard F, Cappellini MD. Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development. Expert Rev Hematol. 2021 Jul;14(7):633-644. doi: 10.1080/17474086.2021.1935854. Epub 2021 Jul 29. PMID: 34324404.

86- Taher A, Hershko C, Cappellini MD. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. Br J Haematol. 2009 Dec;147(5):634-40. doi: 10.1111/j.1365-2141.2009.07848.x. Epub 2009 Aug 13. PMID: 19681884.

87- Haidar R, Musallam KM, Taher AT. Bone disease and skeletal complications in patients with β thalassemia major. Bone. 2011 Mar 1;48(3):425-32. doi: 10.1016/j.bone.2010.10.173. Epub 2010 Oct 28. PMID: 21035575.

88- Kattamis A, Aydinok Y, Taher A. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes. Eur J Haematol. 2018 Sep;101(3):272-282. doi: 10.1111/ejh.13111. Epub 2018 Jul 27. PMID: 29904950.

89- Viprakasit V, Tyan P, Rodmai S, Taher AT. Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition. Orphanet J Rare Dis. 2014 Sep 30;9:131. doi: 10.1186/s13023-014-0131-7. PMID: 25265971; PMCID: PMC4193991.

90- Sawaya RA, Zahed L, Taher A. Peripheral neuropathy in thalassaemia. Ann Saudi Med. 2006 Sep-Oct;26(5):358-63. doi: 10.5144/0256-4947.2006.358. PMID: 17019100; PMCID: PMC6074104.

91- Taher AT, Bou-Fakhredin R, Kreidieh F, Motta I, De Franceschi L, Cappellini MD. Care of patients with hemoglobin disorders during the COVID-19 pandemic: An overview of recommendations. Am J Hematol. 2020 Aug;95(8):E208-E210. doi: 10.1002/ajh.25857. Epub 2020 May 21. PMID: 32394480; PMCID: PMC7272998.

92- Musallam KM, Taher AT, Cappellini MD. Right in time: Mitapivat for the treatment of anemia in α- and β-thalassemia. Cell Rep Med. 2022 Oct 18;3(10):100790. doi: 10.1016/j.xcrm.2022.100790. PMID: 36260990; PMCID: PMC9589095.

93- Finianos A, Matar CF, Taher A. Hepatocellular Carcinoma in β-Thalassemia Patients: Review of the Literature with Molecular Insight into Liver Carcinogenesis. Int J Mol Sci. 2018 Dec 17;19(12):4070. doi: 10.3390/ijms19124070. PMID: 30562917; PMCID: PMC6321074.

94- El Hasbani G, Musallam KM, Uthman I, Cappellini MD, Taher AT. Thalassemia and autoimmune diseases: Absence of evidence or evidence of absence? Blood Rev. 2022 Mar;52:100874. doi: 10.1016/j.blre.2021.100874. Epub 2021 Aug 14. PMID: 34404565.

95- Taher AT, Viprakasit V, Cappellini MD, Kraus D, Cech P, Volz D, Winter E, Nave S, Dukart J, Khwaja O, Koerner A, Hermosilla R, Brugnara C. Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with non-transfusion-dependent β-thalassaemia. Br J Haematol. 2021 Jul;194(2):474-477. doi: 10.1111/bjh.17479. Epub 2021 Apr 30. PMID: 33931857.

96- Mihailescu AM, Musallam KM, Cappellini MD, Taher AT. Less ‘reds’ more ‘blues’: hemoglobin level and depression in non-transfusion-dependent thalassemia. Ann Hematol. 2020 Apr;99(4):903-904. doi: 10.1007/s00277-020-03958-y. Epub 2020 Feb 21. PMID: 32086585.

97- Musallam KM, Taher AT. Mechanisms of renal disease in β-thalassemia. J Am Soc Nephrol. 2012 Aug;23(8):1299-302. doi: 10.1681/ASN.2011111070. Epub 2012 Jun 7. PMID: 22677552.

98- Musallam KM, Vitrano A, Meloni A, Pollina SA, Karimi M, El-Beshlawy A, Hajipour M, Di Marco V, Ansari SH, Filosa A, Ricchi P, Ceci A, Daar S, Vlachaki E, Singer ST, Naserullah ZA, Pepe A, Scondotto S, Dardanoni G, Bonifazi F, Sankaran VG, Vichinsky E, Taher AT, Maggio A; International Working Group on Thalassemia (IWG-THAL). Risk of mortality from anemia and iron overload in nontransfusion-dependent β-thalassemia. Am J Hematol. 2022 Feb 1;97(2):E78-E80. doi: 10.1002/ajh.26428. Epub 2021 Dec 10. PMID: 34862982.

99- Bou-Fakhredin R, De Franceschi L, Motta I, Eid AA, Taher AT, Cappellini MD. Redox Balance in β-Thalassemia and Sickle Cell Disease: A Love and Hate Relationship. Antioxidants (Basel). 2022 May 13;11(5):967. doi: 10.3390/antiox11050967. PMID: 35624830; PMCID: PMC9138068.

100- Taher AT, Musallam KM. A new chelator in the house. Blood. 2012 Apr 5;119(14):3191-2. doi: 10.1182/blood-2012-02-406744. PMID: 22493210.

101- Sharara AI, Rustom LBO, Marrache M, Rimmani HH, Bou Daher H, Koussa S, Taher A. Sofosbuvir/velpatasvir for chronic hepatitis C infection in patients with transfusion-dependent thalassemia. Am J Hematol. 2019 Feb;94(2):E43-E45. doi: 10.1002/ajh.25339. Epub 2018 Nov 29. PMID: 30394575.

102- Taher A, Mehio G, Isma’eel H, Cappellini MD. Stroke in thalassemia: a dilemma. Am J Hematol. 2008 Apr;83(4):343. doi: 10.1002/ajh.21117. PMID: 18183611.

103- Maakaron JE, Cappellini MD, Graziadei G, Ayache JB, Taher AT. Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis. Ann Hepatol. 2013 Jan-Feb;12(1):142-6. PMID: 23293206.

104- Musallam KM, Taher AT. Iron-chelating therapy for transfusional iron overload. N Engl J Med. 2011 Apr 14;364(15):1476; author reply 1477. doi: 10.1056/NEJMc1101838. PMID: 21488787.

105- Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012 Nov 1;120(18):3657-69. doi: 10.1182/blood-2012-05-370098. Epub 2012 Aug 23. PMID: 22919029.

106- Ben Salah N, Bou-Fakhredin R, Mellouli F, Taher AT. Revisiting beta thalassemia intermedia: past, present, and future prospects. Hematology. 2017 Dec;22(10):607-616. doi: 10.1080/10245332.2017.1333246. Epub 2017 Jun 7. PMID: 28589785.

107- Halawi R, Beydoun H, Cappellini MD, Ferla V, Taher A. Hematologic malignancies in thalassemia: Adding new cases to the repertoire. Am J Hematol. 2017 May;92(5):E68-E70. doi: 10.1002/ajh.24681. Epub 2017 Feb 27. PMID: 28195422.

108- Taher AT, Musallam KM, Saliba AN, Graziadei G, Cappellini MD. Hemoglobin level and morbidity in non-transfusion-dependent thalassemia. Blood Cells Mol Dis. 2015 Aug;55(2):108-9. doi: 10.1016/j.bcmd.2015.05.011. Epub 2015 May 30. Erratum in: Blood Cells Mol Dis. 2015 Dec;55(4):419. Garziadei, Giovanna [corrected to Graziadei, Giovanna]. PMID: 26142325.

109- Musallam KM, Cappellini MD, Daar S, Taher AT. Morbidity-free survival and hemoglobin level in non-transfusion-dependent β-thalassemia: a 10-year cohort study. Ann Hematol. 2022 Jan;101(1):203-204. doi: 10.1007/s00277-020-04370-2. Epub 2021 Jan 20. PMID: 33474628.

110- Taher A, Abou-Mourad Y, Abchee A, Zalouaa P, Shamseddine A. Pulmonary thromboembolism in beta-thalassemia intermedia: are we aware of this complication? Hemoglobin. 2002 May;26(2):107-12. doi: 10.1081/hem-120005447. PMID: 12144052.

111- Moukhadder HM, Halawi R, Cappellini MD, Taher AT. Reply to Management of hepatocellular carcinoma in thalassemia and importance of the human factor. Cancer. 2017 May 15;123(6):1073. doi: 10.1002/cncr.30550. Epub 2017 Jan 13. PMID: 28085185.

112- Taher A, Bashshur Z, Shamseddeen WA, Abdulnour RE, Aoun E, Koussa S, Baz P. Ocular findings among thalassemia patients. Am J Ophthalmol. 2006 Oct;142(4):704-5. doi: 10.1016/j.ajo.2006.04.030. PMID: 17011879.

113- Taher AT, Cappellini MD, Musallam KM. Recent advances and treatment challenges in patients with non-transfusion-dependent thalassemia. Blood Rev. 2012 Apr;26 Suppl 1:S1-2. doi: 10.1016/S0268-960X(12)00028-8. PMID: 22631034.

114- Farmakis D, Porter J, Taher A, Domenica Cappellini M, Angastiniotis M, Eleftheriou A. 2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia. Hemasphere. 2022 Jul 29;6(8):e732. doi: 10.1097/HS9.0000000000000732. PMID: 35928543; PMCID: PMC9345633.

115- Bou-Fakhredin R, Dia B, Ghadieh HE, Rivella S, Cappellini MD, Eid AA, Taher AT. CYP450 Mediates Reactive Oxygen Species Production in a Mouse Model of β-Thalassemia through an Increase in 20-HETE Activity. Int J Mol Sci. 2021 Jan 23;22(3):1106. doi: 10.3390/ijms22031106. PMID: 33498614; PMCID: PMC7865490.

116- Isma’eel H, Shamseddeen W, Taher A, Gharzuddine W, Dimassi A, Alam S, Masri L, Khoury M. Ventricular late potentials among thalassemia patients. Int J Cardiol. 2009 Mar 6;132(3):453-5. doi: 10.1016/j.ijcard.2007.08.103. Epub 2008 Mar 4. PMID: 18164497.

117- Cappellini MD, Kattamis A, Viprakasit V, Sutcharitchan P, Pariseau J, Laadem A, Jessent-Ciaravino V, Taher A. Quality of life in patients with β-thalassemia: A prospective study of transfusion-dependent and non-transfusion-dependent patients in Greece, Italy, Lebanon, and Thailand. Am J Hematol. 2019 Oct;94(10):E261-E264. doi: 10.1002/ajh.25584. Epub 2019 Aug 13. PMID: 31321793.

118- Matta BN, Musallam KM, Maakaron JE, Koussa S, Taher AT. A killer revealed: 10-year experience with beta-thalassemia intermedia. Hematology. 2014 Jun;19(4):196-8. doi: 10.1179/1607845413Y.0000000120. Epub 2013 Nov 25. PMID: 24074485.

119- Taher A, Viprakasit V, Cappellini MD, Sutcharitchan P, Ward R, Mahmoud D, Laadem A, Khan A, Gwaltney C, Harding G, Attie K, Zhang X, Zou J, Pariseau J, Hu XH, Kattamis A. Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO© ). Am J Hematol. 2019 Feb;94(2):171-176. doi: 10.1002/ajh.25343. Epub 2018 Nov 26. PMID: 30394579; PMCID: PMC6587527.

120- Taher A, Cappellini MD, Viprakasit V, Sutcharitchan P, Mahmoud D, Laadem A, Khan A, Gwaltney C, Harding G, Attie K, Zhang X, Zou J, Pariseau J, Henry Hu X, Kattamis A. Validation of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO© ). Am J Hematol. 2019 Feb;94(2):177-183. doi: 10.1002/ajh.25344. Epub 2018 Nov 26. PMID: 30394570; PMCID: PMC6587834.

121- Taher AT, Weber S, Han J, Bruederle A, Porter JB. Predicting serum ferritin levels in patients with iron overload treated with the film-coated tablet of deferasirox during the ECLIPSE study. Am J Hematol. 2019 Jan;94(1):E15-E17. doi: 10.1002/ajh.25322. Epub 2018 Nov 15. PMID: 30346059; PMCID: PMC6587503.

122- Taher AT, Musallam KM, Viprakasit V, Porter JB, Cappellini MD. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo. Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):88-90. doi: 10.1016/j.bcmd.2013.08.006. Epub 2013 Sep 13. PMID: 24041597.

123- Beydoun HG, Saliba AN, Taher AT. Deferasirox in thalassemia patients with end-stage renal disease. Am J Hematol. 2016 Oct;91(10):E456-7. doi: 10.1002/ajh.24457. Epub 2016 Jul 14. PMID: 27342388.

124- Mallat NS, Beydoun A, Musallam KM, Koussa S, Taher AT. Deferiprone-induced seizures in a patient with β-thalassemia major. Blood Cells Mol Dis. 2013 Aug;51(2):94-5. doi: 10.1016/j.bcmd.2013.03.002. Epub 2013 Apr 12. PMID: 23587452.

125- Taher AT, Origa R, Perrotta S, Kouraklis A, Belhoul K, Huang V, Han J, Bruederle A, Bobbili P, Duh MS, Porter JB. Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis. Am J Hematol. 2019 Apr;94(4):E96-E99. doi: 10.1002/ajh.25408. Epub 2019 Jan 31. PMID: 30663129; PMCID: PMC6590223.

126- Musallam KM, Taher AT. Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major. Haematologica. 2011 Feb;96(2):e5-6; author reply e7-8. doi: 10.3324/haematol.2010.036061. PMID: 21282714; PMCID: PMC3031678.

127- Wali Y, Hassan T, Charoenkwan P, Trompeter S, Tartaglione I, Origa R, Gamberini MR, Viprakasit V, Izquierdo M, Opio S, Roy T, Taher A. Crushed deferasirox film-coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single-arm, interventional phase 4 study (MIMAS). Am J Hematol. 2022 Aug;97(8):E292-E295. doi: 10.1002/ajh.26598. Epub 2022 May 31. PMID: 35570412.

128- Otrock ZK, Shamseddine AI, Taher AT. Non-Hodgkin disease in beta-thalassemia major. Am J Hematol. 2006 Jan;81(1):62-4. doi: 10.1002/ajh.20463. PMID: 16369971.

129- Jabr FI, Aoun E, Yassine H, Azar C, Taher A. Beta-thalassemia intermedia and Hodgkin lymphoma. Am J Hematol. 2006 Feb;81(2):151. doi: 10.1002/ajh.20478. PMID: 16432853.

130- Morris CR, Kim HY, Klings ES, Wood J, Porter JB, Trachtenberg F, Sweeters N, Olivieri NF, Kwiatkowski JL, Virzi L, Hassell K, Taher A, Neufeld EJ, Thompson AA, Larkin S, Suh JH, Vichinsky EP, Kuypers FA; Thalassemia Clinical Research Network. Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. Br J Haematol. 2015 Jun;169(6):887-98. doi: 10.1111/bjh.13452. Epub 2015 Apr 24. PMID: 25907665; PMCID: PMC4452408.

131- Taher AT, Saliba AN, Kuo KH, Giardina PJ, Cohen AR, Neufeld EJ, Aydinok Y, Kwiatkowski JL, Jeglinski BI, Pietropaolo K, Berk G, Viprakasit V. Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia. Am J Hematol. 2017 Dec;92(12):1356-1361. doi: 10.1002/ajh.24914. Epub 2017 Oct 31. PMID: 28940308.

132- Masrouha KZ, Wazen J, Haddad A, Saadeh F, Taher A, Khoury NJ. Cortical bone invasion in non-transfusion-dependent thalassemia: tumefactive extramedullary hematopoiesis reviewed. Radiol Med. 2016 Aug;121(8):626-34. doi: 10.1007/s11547-016-0638-1. Epub 2016 Apr 23. PMID: 27108419.

133- Taher AT, Musallam KM, El-Beshlawy A, Karimi M, Daar S, Belhoul K, Saned MS, Graziadei G, Cappellini MD. Age-related complications in treatment-naïve patients with thalassaemia intermedia. Br J Haematol. 2010 Aug;150(4):486-9. doi: 10.1111/j.1365-2141.2010.08220.x. Epub 2010 Apr 29. PMID: 20456362.

134- Lai YR, Cappellini MD, Aydinok Y, Porter J, Karakas Z, Viprakasit V, Siritanaratkul N, Kattamis A, Liu R, Izquierdo M, Lasher J, Govindaraju S, Taher A. An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with

non-transfusion-dependent thalassemia (THETIS): 5-year results. Am J Hematol. 2022 Aug;97(8):E281-E284. doi: 10.1002/ajh.26592. Epub 2022 May 27. PMID: 35560253.

135- Cappellini MD, Musallam KM, Marcon A, Taher AT. Coagulopathy in Beta-thalassemia: current understanding and future perspectives. Mediterr J Hematol Infect Dis. 2009 Dec 29;1(1):e2009029. doi: 10.4084/MJHID.2009.029. PMID: 21415997; PMCID: PMC3033163.

136- Taher A, El Rassi F, Ismaeel H, Inati A. Complications of beta-thalassemia intermedia: a 12-year Lebanese experience. Am J Hematol. 2008 Jul;83(7):605-6. doi: 10.1002/ajh.21174. PMID: 18383330.

137- Musallam KM, Vitrano A, Meloni A, Addario Pollina S, Di Marco V, Hussain Ansari S, Filosa A, Ricchi P, Ceci A, Daar S, Vlachaki E, Singer ST, Naserullah ZA, Pepe A, Scondotto S, Dardanoni G, Karimi M, El-Beshlawy A, Hajipour M, Bonifazi F, Vichinsky E, Taher AT, Sankaran VG, Maggio A; International Working Group on Thalassemia (IWG-THAL). Primary HBB gene mutation severity and long-term outcomes in a global cohort of β-thalassaemia. Br J Haematol. 2022 Jan;196(2):414-423. doi: 10.1111/bjh.17897. Epub 2021 Oct 25. PMID: 34697800.

138- Mallat NS, Wehbe D, Haddad A, Cappellini MD, Marcon A, Koussa S, Abboud MR, Radwan A, Taher AT. Priapism, an emerging complication in β-thalassemia intermedia patients. Hemoglobin. 2014;38(5):351-4. doi: 10.3109/03630269.2014.960087. PMID: 25271993.

139- Bou-Fakhredin R, Ghanem NN, Kreidieh F, Tabbikha R, Daadaa H, Ajouz J, Koussa S, Taher AT. A Report on the Education, Employment and Marital Status of Thalassemia Patients from a Tertiary Care Center in the Middle East. Hemoglobin. 2020 Jul;44(4):278-283. doi: 10.1080/03630269.2020.1797776. Epub 2020 Jul 29. PMID: 32727228.

140- Taher A, Cappellini MD. Update on the use of deferasirox in the management of iron overload. Ther Clin Risk Manag. 2009;5:857-68. doi: 10.2147/tcrm.s5497. Epub 2009 Nov 2. PMID: 19898650; PMCID: PMC2773754.

141- Morris CR, Kim HY, Wood J, Porter JB, Klings ES, Trachtenberg FL, Sweeters N, Olivieri NF, Kwiatkowski JL, Virzi L, Singer ST, Taher A, Neufeld EJ, Thompson AA, Sachdev V, Larkin S, Suh JH, Kuypers FA, Vichinsky EP; Thalassemia Clinical Research Network. Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica. 2013 Sep;98(9):1359-67. doi: 10.3324/haematol.2012.082065. Epub 2013 Apr 12. PMID: 23585527; PMCID: PMC3762091.

142- Viprakasit V, Ajlan A, Aydinok Y, Al Ebadi BAA, Dewedar H, Ibrahim AS, Ragab L, Trad O, Wataify AS, Wong LLL, Taher AT. MRI for the diagnosis of cardiac and liver iron

overload in patients with transfusion-dependent thalassemia: An algorithm to guide clinical use when availability is limited. Am J Hematol. 2018 Jun;93(6):E135-E137. doi: 10.1002/ajh.25075. Epub 2018 Mar 15. PMID: 29473204.

143- Elhajj I, Chehal A, Shamseddine A, Mourad YA, Taher A. Hb H disease and multiple myeloma. Hemoglobin. 2004 Feb;28(1):79-82. doi: 10.1081/hem-120028892. PMID: 15008270.

144- Musallam KM, Cappellini MD, Daar S, Karimi M, El-Beshlawy A, Graziadei G, Magestro M, Wulff J, Pietri G, Taher AT. Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: the ORIENT study. Haematologica. 2014 Nov;99(11):e218-21. doi: 10.3324/haematol.2013.097220. Epub 2014 Jul 4. PMID: 24997148; PMCID: PMC4222462.

145- Taher AT, Karakas Z, Cassinerio E, Siritanaratkul N, Kattamis A, Maggio A, Rivella S, Hollaender N, Mahuzier B, Gadbaw B, Aydinok Y. Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study. Blood. 2018 Jan 11;131(2):263-265. doi: 10.1182/blood-2017-06-790121. Epub 2017 Nov 2. PMID: 29097381; PMCID: PMC5757682.

146- Inati A, Kahale M, Perrine SP, Chui DH, Taher AT, Koussa S, Abi Nasr T, Abbas HA, Ghalie RG. A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia. Br J Haematol. 2014 Feb;164(3):456-8. doi: 10.1111/bjh.12635. Epub 2013 Nov 13. PMID: 24224649; PMCID: PMC3904791.

147- Taher A, Shammaa D, Bazarbachi A, Itani D, Zaatari G, Greige L, Otrock ZK, Mahfouz RA. Absence of JAK2 V617F mutation in thalassemia intermedia patients. Mol Biol Rep. 2009 Jul;36(6):1555-7. doi: 10.1007/s11033-008-9350-0. Epub 2008 Sep 10. PMID: 18781401.

148- Moukhadder HM, Roumi JE, Bou-Fakhredin R, Taher AT. Hepatocellular Carcinoma in a β-Thalassemia Intermedia Patient: Yet Another Case in the Expanding Epidemic. Hemoglobin. 2018 Jan;42(1):58-60. doi: 10.1080/03630269.2018.1434197. Epub 2018 Mar 1. PMID: 29493312.

149- Maakaron JE, Musallam KM, Ayache JB, Jabbour M, Tawil AN, Taher AT. A liver mass in an iron-overloaded thalassaemia intermedia patient. Br J Haematol. 2013 Apr;161(1):1. doi: 10.1111/bjh.12195. Epub 2013 Jan 7. PMID: 23294457.

150- Carpenter JP, Roughton M, Pennell DJ; Myocardial Iron in Thalassemia (MINT) Investigators. International survey of T2* cardiovascular magnetic resonance in β-thalassemia major. Haematologica. 2013 Sep;98(9):1368-74. doi: 10.3324/haematol.2013.083634. Epub 2013 Jun 28. PMID: 23812939; PMCID: PMC3762092.

151- Youssry I, Soliman N, Ghamrawy M, Samy RM, Nasr A, Abdel Mohsen M, ElShahaat M, Bou Fakhredin R, Taher A. Circulating microparticles and the risk of thromboembolic events in Egyptian beta thalassemia patients. Ann Hematol. 2017 Apr;96(4):597-603. doi: 10.1007/s00277-017-2925-x. Epub 2017 Feb 7. PMID: 28168351.

152- Taher A, Musallam KM, El Rassi F, Duca L, Inati A, Koussa S, Cappellini MD. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol. 2009 Sep;146(5):569-72. doi: 10.1111/j.1365-2141.2009.07810.x. Epub 2009 Jul 13. PMID: 19604239.

153- Cappellini MD, Porter J, Origa R, Forni GL, Voskaridou E, Galactéros F, Taher AT, Arlet JB, Ribeil JA, Garbowski M, Graziadei G, Brouzes C, Semeraro M, Laadem A, Miteva D, Zou J, Sung V, Zinger T, Attie KM, Hermine O. Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study. Haematologica. 2019 Mar;104(3):477-484. doi: 10.3324/haematol.2018.198887. Epub 2018 Oct 18. PMID: 30337358; PMCID: PMC6395345.

154- Taher A, Sheikh-Taha M. Hydroxyurea use in Lebanese patients with beta-thalassemia intermedia. J Pediatr Hematol Oncol. 2006 Feb;28(2):107. doi: 10.1097/01.mph.0000200671.39549.2b. PMID: 16462586.

155- Habib A, Kunzelmann C, Shamseddeen W, Zobairi F, Freyssinet JM, Taher A. Elevated levels of circulating procoagulant microparticles in patients with beta-thalassemia intermedia. Haematologica. 2008 Jun;93(6):941-2. doi: 10.3324/haematol.12460. Epub 2008 May 6. PMID: 18460647.

156- Musallam KM, Sankaran VG, Cappellini MD, Duca L, Nathan DG, Taher AT. Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia. Blood. 2012 Jan 12;119(2):364-7. doi: 10.1182/blood-2011-09-382408. Epub 2011 Nov 17. PMID: 22096240.

157- Musallam KM, Beydoun A, Hourani R, Nasreddine W, Raad R, Koussa S, Taher AT. Brain magnetic resonance angiography in splenectomized adults with β-thalassemia intermedia. Eur J Haematol. 2011 Dec;87(6):539-46. doi: 10.1111/j.1600-0609.2011.01706.x. PMID: 21913989.

158- Porter JB, Cappellini MD, Kattamis A, Viprakasit V, Musallam KM, Zhu Z, Taher AT. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. Br J Haematol. 2017 Jan;176(2):288-299. doi: 10.1111/bjh.14373. Epub 2016 Dec 5. PMID: 27917462; PMCID: PMC5248634.

159- Ziyadeh FN, Musallam KM, Mallat NS, Mallat S, Jaber F, Mohamed AA, Koussa S, Taher AT. Glomerular hyperfiltration and proteinuria in transfusion-independent patients

with β-thalassemia intermedia. Nephron Clin Pract. 2012;121(3-4):c136-43. doi: 10.1159/000339787. Epub 2012 Dec 8. PMID: 23235469.

160- Musallam KM, Cappellini MD, Taher AT. Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with β-thalassemia intermedia. Blood Cells Mol Dis. 2013 Jun;51(1):35-8. doi: 10.1016/j.bcmd.2013.01.015. Epub 2013 Feb 18. PMID: 23425967.

161- Brancaleoni V, Moukhadder HM, Consonni D, Koussa S, Di Pierro E, Cappellini MD, Taher A. Common fetal hemoglobin variants in Lebanese patients bearing the codon 29 beta gene mutation associated with different thalassemia phenotypes. Ann Hematol. 2019 Apr;98(4):833-840. doi: 10.1007/s00277-018-3567-3. Epub 2018 Nov 30. PMID: 30506348.

162- Taher AT, Musallam KM, Nasreddine W, Beydoun A. Covert brain ischaemia in splenectomised adults with thalassemia intermedia: An emerging entity. Thromb Haemost. 2010 Sep;104(3):652-3. doi: 10.1160/TH10-03-0200. Epub 2010 Jun 29. PMID: 20589318.

163- Karimi M, Musallam KM, Cappellini MD, Daar S, El-Beshlawy A, Belhoul K, Saned MS, Temraz S, Koussa S, Taher AT. Risk factors for pulmonary hypertension in patients with β thalassemia intermedia. Eur J Intern Med. 2011 Dec;22(6):607-10. doi: 10.1016/j.ejim.2011.05.013. Epub 2011 Jun 29. PMID: 22075289.

164- Khoury B, Musallam KM, Abi-Habib R, Bazzi L, Ward ZA, Succar J, Halawi R, Hankir A, Koussa S, Taher AT. Prevalence of depression and anxiety in adult patients with β-thalassemia major and intermedia. Int J Psychiatry Med. 2012;44(4):291-303. doi: 10.2190/PM.44.4.a. PMID: 23885513.

165- Mallat NS, Musallam KM, Mallat SG, Ziyadeh FN, Koussa S, Taher AT. End stage renal disease in six patients with beta-thalassemia intermedia. Blood Cells Mol Dis. 2013 Oct;51(3):146-8. doi: 10.1016/j.bcmd.2013.05.001. Epub 2013 May 31. PMID: 23732019.

166- Taher AT, Cappellini MD, Aydinok Y, Porter JB, Karakas Z, Viprakasit V, Siritanaratkul N, Kattamis A, Wang C, Zhu Z, Joaquin V, Uwamahoro MJ, Lai YR. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Blood Cells Mol Dis. 2016 Mar;57:23-9. doi: 10.1016/j.bcmd.2015.11.002. Epub 2015 Nov 11. PMID: 26852651.

167- Youssry I, Abdel-Salam A, Ismail R, Bou-Fakhredin R, Mohamed Samy R, Ezz El-Deen F, Taher AT. Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience. Hemoglobin. 2017 Jul-Nov;41(4-6):267-273. doi: 10.1080/03630269.2017.1408646. Epub 2017 Dec 18. P

168- Musallam KM, Nasreddine W, Beydoun A, Hourani R, Hankir A, Koussa S, Haidar M, Taher AT. Brain positron emission tomography in splenectomized adults with β-thalassemia intermedia: uncovering yet another covert abnormality. Ann Hematol. 2012 Feb;91(2):235-41. doi: 10.1007/s00277-011-1291-3. Epub 2011 Jul 13. PMID: 21750926.

169- Taher AT, Porter JB, Kattamis A, Viprakasit V, Cappellini MD. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. Drug Des Devel Ther. 2016 Dec 15;10:4073-4078. doi: 10.2147/DDDT.S117080. PMID: 28008230; PMCID: PMC5170616.

170- El-Beshlawy A, El Accaoui R, Abd El-Sattar M, Gamal El-Deen MH, Youssry I, Shaheen N, Hamdy M, El-Ghamrawy M, Taher A. Effect of L-carnitine on the physical fitness of thalassemic patients. Ann Hematol. 2007 Jan;86(1):31-4. doi: 10.1007/s00277-006-0181-6. Epub 2006 Oct 10. PMID: 17031691.

171- Musallam K, Cappellini MD, Taher A. Challenges associated with prolonged survival of patients with thalassemia: transitioning from childhood to adulthood. Pediatrics. 2008 May;121(5):e1426-9. doi: 10.1542/peds.2007-1944. PMID: 18450884.

172- Inati A, Musallam KM, Wood JC, Taher AT. Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease. Blood. 2010 Apr 8;115(14):2980-1; author reply 2981-2. doi: 10.1182/blood-2009-09-243568. PMID: 20378761.

173- Saliba AN, Musallam KM, Cappellini MD, Graziadei G, Daar S, Viprakasit V, Taher AT. Serum ferritin values between 300 and 800 ng/mL in nontransfusion-dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable. Am J Hematol. 2017 Mar;92(3):E35-E37. doi: 10.1002/ajh.24628. Epub 2017 Feb 1. PMID: 28052365.

174- Belhoul KM, Bakir ML, Saned MS, Kadhim AM, Musallam KM, Taher AT. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major. Ann Hematol. 2012 Jul;91(7):1107-14. doi: 10.1007/s00277-012-1412-7. Epub 2012 Jan 28. PMID: 22281991.

175- Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, Elalfy MS, Sutcharitchan P, Li CK, Ibrahim H, Viprakasit V, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood. 2010 Mar 25;115(12):2364-71. doi: 10.1182/blood-2009-04-217455. Epub 2009 Dec 8. PMID: 19996412.

176- Pathare A, Taher A, Daar S. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol. 2010

Apr;89(4):405-9. doi: 10.1007/s00277-009-0838-z. Epub 2009 Oct 2. PMID: 19798501; PMCID: PMC2824843.

177- Otrock ZK, Mahfouz RA, Charafeddine KM, Rayes RF, Zahed LF, Taher AT. Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis. Ann Hematol. 2008 Nov;87(11):947-8. doi: 10.1007/s00277-008-0497-5. Epub 2008 Apr 29. PMID: 18443790.

178- El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, Sobh H, Hamdy M, Sharaf I, Mostafa A, Shaker O, Hoffbrand AV, Taher A. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Ann Hematol. 2008 Jul;87(7):545-50. doi: 10.1007/s00277-008-0471-2. Epub 2008 Mar 20. PMID: 18351337.

179- El Rassi FA, Ismaeel HA, Koussa SC, Taher AT. Myocardial infarction in a 28-year-old thalassemia intermedia patient. Clin Appl Thromb Hemost. 2009 Jul-Aug;15(4):467-9. doi: 10.1177/1076029608315166. Epub 2008 Apr 2. PMID: 18387984.

180- El-Beshlawy A, Youssry I, El-Saidi S, El Accaoui R, Mansi Y, Makhlouf A, Taher A. Pulmonary hypertension in beta-thalassemia major and the role of L-carnitine therapy. Pediatr Hematol Oncol. 2008 Dec;25(8):734-43. doi: 10.1080/08880010802244035. PMID: 19065439.

181- Lederer CW, Basak AN, Aydinok Y, Christou S, El-Beshlawy A, Eleftheriou A, Fattoum S, Felice AE, Fibach E, Galanello R, Gambari R, Gavrila L, Giordano PC, Grosveld F, Hassapopoulou H, Hladka E, Kanavakis E, Locatelli F, Old J, Patrinos GP, Romeo G, Taher A, Traeger-Synodinos J, Vassiliou P, Villegas A, Voskaridou E, Wajcman H, Zafeiropoulos A, Kleanthous M. An electronic infrastructure for research and treatment of the thalassemias and other hemoglobinopathies: the Euro-mediterranean ITHANET project. Hemoglobin. 2009;33(3):163-76. doi: 10.1080/03630260903089177. PMID: 19657830.

182- Nassar AH, Naja M, Cesaretti C, Eprassi B, Cappellini MD, Taher A. Pregnancy outcome in patients with beta-thalassemia intermedia at two tertiary care centers, in Beirut and Milan. Haematologica. 2008 Oct;93(10):1586-7. doi: 10.3324/haematol.13152. Epub 2008 Aug 12. PMID: 18698079.

183- Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Origa R, Karakas Z, Habr D, Zhu Z, Cappellini MD. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. Br J Haematol. 2015 Jan;168(2):284-90. doi: 10.1111/bjh.13119. Epub 2014 Sep 12. PMID: 25212456.

184- Saliba AN, Taher AT. Comment on “deferiprone versus deferoxamine in thalassemia intermedia: results from a 5-year long-term Italian multicenter randomized

clinical trial”. Am J Hematol. 2015 Sep;90(9):E192-3. doi: 10.1002/ajh.24080. Epub 2015 Jul 22. PMID: 26044060.

185- Lederer CW, Basak AN, Aydinok Y, Christou S, El-Beshlawy A, Eleftheriou A, Fattoum S, Felice AE, Fibach E, Galanello R, Gambari R, Gavrila L, Giordano PC, Grosveld F, Hassapopoulou H, Hladka E, Kanavakis E, Locatelli F, Old J, Patrinos GP, Romeo G, Taher A, Traeger-Synodinos J, Vassiliou P, Villegas A, Voskaridou E, Wajcman H, Zafeiropoulos A, Kleanthous M. An electronic infrastructure for research and treatment of the thalassemias and other hemoglobinopathies: the Euro-mediterranean ITHANET project. Hemoglobin. 2009;33(3):163-76. doi: 10.1080/03630260903089177. PMID: 19657830.

186- Nassar AH, Naja M, Cesaretti C, Eprassi B, Cappellini MD, Taher A. Pregnancy outcome in patients with beta-thalassemia intermedia at two tertiary care centers, in Beirut and Milan. Haematologica. 2008 Oct;93(10):1586-7. doi: 10.3324/haematol.13152. Epub 2008 Aug 12. PMID: 18698079.

187- Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Origa R, Karakas Z, Habr D, Zhu Z, Cappellini MD. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. Br J Haematol. 2015 Jan;168(2):284-90. doi: 10.1111/bjh.13119. Epub 2014 Sep 12. PMID: 25212456.

188- Saliba AN, Taher AT. Comment on “deferiprone versus deferoxamine in thalassemia intermedia: results from a 5-year long-term Italian multicenter randomized clinical trial”. Am J Hematol. 2015 Sep;90(9):E192-3. doi: 10.1002/ajh.24080. Epub 2015 Jul 22. PMID: 26044060.

189- Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Origa R, Karakas Z, Habr D, Zhu Z, Cappellini MD. Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox. Eur J Haematol. 2014 Jun;92(6):521-6. doi: 10.1111/ejh.12270. Epub 2014 Mar 25. PMID: 24460655; PMCID: PMC4232858.

190- Isma’eel H, Chafic AH, El Rassi F, Inati A, Koussa S, Daher R, Gharzuddin W, Alam S, Taher A. Relation between iron-overload indices, cardiac echo-Doppler, and biochemical markers in thalassemia intermedia. Am J Cardiol. 2008 Aug 1;102(3):363-7. doi: 10.1016/j.amjcard.2008.03.066. Epub 2008 May 29. PMID: 18638603.

191- Karimi M, Haghpanah S, Taher AT, Cappellini MD. β-Thalassemia: New Therapeutic Modalities, Genetics, Complications, and Quality of Life. Anemia. 2012;2012:902067. doi: 10.1155/2012/902067. Epub 2012 Sep 18. PMID: 23019522; PMCID: PMC3457590.

192- Viprakasit V, Gattermann N, Lee JW, Porter JB, Taher AT, Habr D, Martin N, Domokos G, Cappellini MD. Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. Blood Transfus. 2013 Jan;11(1):108-22. doi: 10.2450/2012.0012-12. Epub 2012 Jul 12. PMID: 22871821; PMCID: PMC3557481.

193- Taher A, Al Jefri A, Elalfy MS, Al Zir K, Daar S, Rofail D, Baladi JF, Habr D, Kriemler-Krahn U, El-Beshlawy A. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial. Acta Haematol. 2010;123(4):220-5. doi: 10.1159/000313447. Epub 2010 Apr 27. PMID: 20424435.

194- Nassar AH, Usta IM, Rechdan JB, Koussa S, Inati A, Taher AT. Pregnancy in patients with beta-thalassemia intermedia: outcome of mothers and newborns. Am J Hematol. 2006 Jul;81(7):499-502. doi: 10.1002/ajh.20654. PMID: 16755576.

195- El Khoury J, Taher A, Kurban M, Kibbi AG, Abbas O. Livedoid vasculopathy associated with sickle cell trait: significant improvement on aspirin treatment. Int Wound J. 2012 Jun;9(3):344-7. doi: 10.1111/j.1742-481X.2011.00882.x. Epub 2011 Nov 1. PMID: 22044499; PMCID: PMC7950644.

196- Fathallah H, Taher A, Bazarbachi A, Atweh GF. Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease. Blood Cells Mol Dis. 2009 Jul-Aug;43(1):58-62. doi: 10.1016/j.bcmd.2009.02.006. Epub 2009 Apr 5. PMID: 19346141; PMCID: PMC2707824.

197- Inati A, Khoriaty E, Musallam KM, Taher AT. Iron chelation therapy for patients with sickle cell disease and iron overload. Am J Hematol. 2010 Oct;85(10):782-6. doi: 10.1002/ajh.21806. PMID: 20721892.

198- Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Habr D, Ros J, Zhang Y, Cappellini MD. Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. Am J Hematol. 2013 Jun;88(6):503-6. doi: 10.1002/ajh.23445. Epub 2013 May 13. PMID: 23553596; PMCID: PMC3698696.

199- Fucharoen S, Inati A, Siritanaratku N, Thein SL, Wargin WC, Koussa S, Taher A, Chaneim N, Boosalis M, Berenson R, Perrine SP. A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. Br J Haematol. 2013 May;161(4):587-93. doi: 10.1111/bjh.12304. Epub 2013 Mar 27. PMID: 23530969; PMCID: PMC3970579.

200- Taher AT, Origa R, Perrotta S, Kouraklis A, Ruffo GB, Kattamis A, Goh AS, Huang V, Zia A, Herranz RM, Porter JB. Patient-reported outcomes from a randomized phase II

study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias. Health Qual Life Outcomes. 2018 Nov 19;16(1):216. doi: 10.1186/s12955-018-1041-5. PMID: 30453981; PMCID: PMC6245526.

201- Musallam KM, Taher AT, Duca L, Cesaretti C, Halawi R, Cappellini MD. Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with β thalassemia intermedia. Blood Cells Mol Dis. 2011 Dec 15;47(4):232-4. doi: 10.1016/j.bcmd.2011.07.005. Epub 2011 Aug 23. PMID: 21865063.

202- Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica. 2012 Jun;97(6):842-8. doi: 10.3324/haematol.2011.049957. Epub 2012 Jan 22. PMID: 22271905; PMCID: PMC3366648.

203- Puehringer H, Najmabadi H, Law HY, Krugluger W, Viprakasit V, Pissard S, Baysal E, Taher A, Farra C, Al-Ali A, Al-Ateeq S, Oberkanins C. Validation of a reverse-hybridization StripAssay for the simultaneous analysis of common alpha-thalassemia point mutations and deletions. Clin Chem Lab Med. 2007;45(5):605-10. doi: 10.1515/CCLM.2007.125. PMID: 17484620.

204- El-Beshlawy A, Ragab L, Fattah AA, Ibrahim IY, Hamdy M, Makhlouf A, Aoun E, Hoffbrand V, Taher A. Improvement of cardiac function in thalassemia major treated with L-carnitine. Acta Haematol. 2004;111(3):143-8. doi: 10.1159/000076522. PMID: 15034235.

205- Taher AT, Musallam KM, Wood JC, Cappellini MD. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. Am J Hematol. 2010 Apr;85(4):288-90. doi: 10.1002/ajh.21626. PMID: 20143405.

206- Porter JB, Wood J, Olivieri N, Vichinsky EP, Taher A, Neufeld E, Giardina P, Thompson A, Moore B, Evans P, Kim HY, Macklin EA, Trachtenberg F. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson. 2013 May 20;15(1):38. doi: 10.1186/1532-429X-15-38. PMID: 23688265; PMCID: PMC3669105.

207- Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Habr D, Ros J, Zhu Z, Cappellini MD. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol. 2013 Nov;92(11):1485-93. doi: 10.1007/s00277-013-1808-z. Epub 2013 Jun 18. PMID: 23775581; PMCID: PMC3790249.

208- Kutlar A, Reid ME, Inati A, Taher AT, Abboud MR, El-Beshlawy A, Buchanan GR, Smith H, Ataga KI, Perrine SP, Ghalie RG. A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2013 Nov;88(11):E255-60. doi: 10.1002/ajh.23533. Epub 2013 Oct 3. PMID: 23828223.

209- Isma’eel H, Arnaout MS, Shamseddeen W, Mahfouz R, Zeineh N, Jradi O, Taher A. Screening for inherited thrombophilia might be warranted among Eastern Mediterranean sickle-beta-0 thalassemia patients. J Thromb Thrombolysis. 2006 Oct;22(2):121-3. doi: 10.1007/s11239-006-8953-3. PMID: 17008978.

210- Pennell DJ, Porter JB, Piga A, Lai Y, El-Beshlawy A, Belhoul KM, Elalfy M, Yesilipek A, Kilinç Y, Lawniczek T, Habr D, Weisskopf M, Zhang Y, Aydinok Y; CORDELIA study investigators. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood. 2014 Mar 6;123(10):1447-54. doi: 10.1182/blood-2013-04-497842. Epub 2014 Jan 2. PMID: 24385534; PMCID: PMC3945858.

211- Porter JB, Elalfy M, Taher A, Aydinok Y, Lee SH, Sutcharitchan P, El-Ali A, Han J, El-Beshlawy A. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia. Eur J Haematol. 2017 Mar;98(3):280-288. doi: 10.1111/ejh.12830. Epub 2017 Jan 13. PMID: 27859648.

212- Taher AT, Porter J, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Ros J, Zhang Y, Habr D, Cappellini MD. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 2012 Aug 2;120(5):970-7. doi: 10.1182/blood-2012-02-412692. Epub 2012 May 15. PMID: 22589472.

213- Taher A, El Rassi F, Isma’eel H, Koussa S, Inati A, Cappellini MD. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica. 2008 Oct;93(10):1584-6. doi: 10.3324/haematol.13098. Epub 2008 Aug 25. PMID: 18728025.

214- Sheikh-Taha M, Koussa S, Inati A, Taher A. Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient. Hemoglobin. 2007;31(4):499-501. doi: 10.1080/03630260701641211. PMID: 17994386.

215- Taher A, Elalfy MS, Al Zir K, Daar S, Al Jefri A, Habr D, Kriemler-Krahn U, Roubert B, El-Beshlawy A. Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study. Eur J

Haematol. 2011 Oct;87(4):349-54. doi: 10.1111/j.1600-0609.2011.01661.x. Epub 2011 Jul 26. PMID: 21668501; PMCID: PMC3229710.

216- Musallam KM, Motta I, Salvatori M, Fraquelli M, Marcon A, Taher AT, Cappellini MD. Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia. Blood Cells Mol Dis. 2012 Oct 15-Dec 15;49(3-4):136-9. doi: 10.1016/j.bcmd.2012.06.001. Epub 2012 Jun 21. PMID: 22727143.

217- Musallam KM, Cappellini MD, Wood JC, Motta I, Graziadei G, Tamim H, Taher AT. Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica. 2011 Nov;96(11):1605-12. doi: 10.3324/haematol.2011.047852. Epub 2011 Jul 26. PMID: 21791471; PMCID: PMC3208677.

218- Otrock ZK, Azar ST, Shamseddeen WA, Habr D, Inati A, Koussa S, Mahfouz RA, Taher AT. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol. 2006 Sep;85(9):605-9. doi: 10.1007/s00277-006-0136-y. Epub 2006 Jul 8. PMID: 16830143.

219- Porter JB, Taher AT, Cappellini MD, Vichinsky EP. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.]. Hemoglobin. 2008;32(6):601-7. doi: 10.1080/03630260802342008. PMID: 19065340.

220- Taher AT, Origa R, Perrotta S, Kourakli A, Ruffo GB, Kattamis A, Goh AS, Cortoos A, Huang V, Weill M, Merino Herranz R, Porter JB. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. Am J Hematol. 2017 May;92(5):420-428. doi: 10.1002/ajh.24668. Epub 2017 Feb 18. PMID: 28142202; PMCID: PMC6585741.

221- Inati A, Kahale M, Sbeiti N, Cappellini MD, Taher AT, Koussa S, Nasr TA, Musallam KM, Abbas HA, Porter JB. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Pediatr Blood Cancer. 2017 Jan;64(1):188-196. doi: 10.1002/pbc.26213. Epub 2016 Aug 31. PMID: 27576370.

222- Reid ME, El Beshlawy A, Inati A, Kutlar A, Abboud MR, Haynes J Jr, Ward R, Sharon B, Taher AT, Smith W, Manwani D, Ghalie RG. A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2014 Jul;89(7):709-13. doi: 10.1002/ajh.23725. Epub 2014 Apr 15. PMID: 24677033.

223- Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica. 2011 Jan;96(1):48-54. doi: 10.3324/haematol.2010.031468. Epub 2010 Nov 11. PMID: 21071497; PMCID: PMC3012764.

224- Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, Clark J, Habr D, Porter JB. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009 Dec;147(5):752-9. doi: 10.1111/j.1365-2141.2009.07908.x. Epub 2009 Sep 18. PMID: 19764988; PMCID: PMC2779992.

225- Chehal A, Taher A, Shamseddine A. Sicklemia with multi-organ failure syndrome and thrombotic thrombocytopenic purpura. Hemoglobin. 2002 Nov;26(4):345-51. doi: 10.1081/hem-120016371. PMID: 12484629.

226- Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A; EPIC Study Investigators. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010 Apr;95(4):557-66. doi: 10.3324/haematol.2009.014696. Epub 2009 Nov 30. PMID: 19951979; PMCID: PMC2857545.

227- Porter JB, Lin KH, Beris P, Forni GL, Taher A, Habr D, Domokos G, Roubert B, Thein SL; EPIC study investigators. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. Eur J Haematol. 2011 Oct;87(4):338-48. doi: 10.1111/j.1600-0609.2011.01660.x. Epub 2011 Jul 29. PMID: 21649735; PMCID: PMC3229702.

228- Saliba AN, Taher AT, Tamim H, Harb AR, Mailhac A, Radwan A, Jamali FR. Impact of Resident Involvement in Surgery (IRIS-NSQIP): Looking at the Bigger Picture Based on the American College of Surgeons-NSQIP Database. J Am Coll Surg. 2016 Jan;222(1):30-40. doi: 10.1016/j.jamcollsurg.2015.10.011. Epub 2015 Oct 27. PMID: 26601821.

229- Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003 Apr;121(1):187-9. doi: 10.1046/j.1365-2141.2003.04240.x. PMID: 12670352.

230- Taher AT. Clinical utility of serum ferritin thresholds for guiding iron chelation therapy when magnetic resonance imaging is unavailable in patients with non-transfusion-dependent thalassaemias – response to Ang et al. Br J Haematol. 2017 Mar;176(6):989-990. doi: 10.1111/bjh.14018. Epub 2016 Mar 11. PMID: 26969908.

231- Roghi A, Cappellini MD, Wood JC, Musallam KM, Patrizia P, Fasulo MR, Cesaretti C, Taher AT. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Ann Hematol. 2010 Jun;89(6):585-9. doi: 10.1007/s00277-009-0879-3. Epub 2009 Dec 17. PMID: 20016898.

232- Inati A, Musallam KM, Wood JC, Sheikh-Taha M, Daou L, Taher AT. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease. Eur J Haematol. 2009 Dec 1;83(6):565-71. doi: 10.1111/j.1600-0609.2009.01345.x. Epub 2009 Sep 8. PMID: 19737308.

233- Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, Kriemler-Krahn U, Hmissi A, Al Jefri A. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009 Jun;82(6):458-65. doi: 10.1111/j.1600-0609.2009.01228.x. Epub 2009 Jan 28. PMID: 19187278; PMCID: PMC2730551.

234- Daar S, Pathare A, Nick H, Kriemler-Krahn U, Hmissi A, Habr D, Taher A. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol. 2009 Jun;82(6):454-7. doi: 10.1111/j.1600-0609.2008.01204.x. Epub 2008 Dec 22. PMID: 19191863; PMCID: PMC2730549.

235- Musallam KM, Khoury B, Abi-Habib R, Bazzi L, Succar J, Halawi R, Hankir A, Koussa S, Taher AT. Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights. Eur J Haematol. 2011 Jul;87(1):73-9. doi: 10.1111/j.1600-0609.2011.01623.x. PMID: 21480999.

236- Musallam KM, Cappellini MD, Daar S, El-Beshlawy A, Taher AT. Magnitude of cumulative iron overload correlates with the severity of anemia in untreated non-transfusion-dependent β-thalassemia. Ann Hematol. 2022 Nov 14. doi: 10.1007/s00277-022-05046-9. Epub ahead of print. PMID: 36376596.

237- Taher AT, Musallam KM, Khalife M, Barada K. Hepatitis C antiviral response in thalassemia: what is the role of liver iron concentration? Ann Hematol. 2009 Oct;88(10):1033-4. doi: 10.1007/s00277-009-0713-y. Epub 2009 Mar 3. PMID: 19255758.

238- Daar S, Musallam KM, Taher A, Pathare A. Association between cardiac T2* magnetic resonance imaging values and endocrine function tests in patients with

β-thalassemia major. Blood Cells Mol Dis. 2014 Jan;52(1):50-1. doi: 10.1016/j.bcmd.2013.08.001. Epub 2013 Sep 2. PMID: 24007801.

239- Taher A, Elalfy MS, Al Zir K, Daar S, Al Jefri A, Habr D, Kriemler-Krahn U, El-Ali A, Roubert B, El-Beshlawy A. Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia. Eur J Haematol. 2011 Oct;87(4):355-65. doi: 10.1111/j.1600-0609.2011.01662.x. Epub 2011 Jul 31. PMID: 21668502; PMCID: PMC3229712.

240- Abou Mourad Y, Shamseddine A, Hamdan A, Koussa S, Taher A. Report of a rare co-incidence of congenital factor V deficiency and thalassemia intermedia in a family. Ann Saudi Med. 2004 Jul-Aug;24(4):301-2. doi: 10.5144/0256-4947.2004.301. PMID: 15387502; PMCID: PMC6148106.

241- Chehal A, Aoun E, Koussa S, Skoury H, Koussa S, Taher A. Hypertransfusion: a successful method of treatment in thalassemia intermedia patients with spinal cord compression secondary to extramedullary hematopoiesis. Spine (Phila Pa 1976). 2003 Jul 1;28(13):E245-9. doi: 10.1097/01.BRS.0000067282.47308.4D. PMID: 12838112.

242- Taher A, Sheikh-Taha M, Sharara A, Inati A, Koussa S, Ellis G, Dhillon AP, Hoffbrand AV. Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study. Acta Haematol. 2005;114(3):146-9. doi: 10.1159/000087888. PMID: 16227677.

243- Inati A, Taher A, Ghorra S, Koussa S, Taha M, Aoun E, Sharara AI. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. Br J Haematol. 2005 Aug;130(4):644-6. doi: 10.1111/j.1365-2141.2005.05645.x. PMID: 16098081.

244- Taher A, Isma’eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, Cappellini MD. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006 Oct;96(4):488-91. PMID: 17003927.

245- Sheikh-Taha M, Koussa S, Taher A. Isolated thrombocytopenia associated with hydroxyurea/deferiprone (L1) therapy in a sickle beta thalassemia patient. Haematologica. 2006 Jun;91(6 Suppl):ECR25. PMID: 16785128.

246- Mahmoud A, Musallam KM, Taher AT. Iron and hepatitis C: what can we learn from thalassemia major? Liver Int. 2008 Jul;28(6):892-3; author reply 893. doi: 10.1111/j.1478-3231.2008.01769.x. PMID: 18647144.

247- Sharara AI, Aoun E, Koussa S, Inati A, Taher A. Treatment of acute hepatitis C in a child with thalassemia major using weight-based peginterferon alpha-2b. J Gastroenterol Hepatol. 2006 Jul;21(7):1221. doi: 10.1111/j.1440-1746.2006.04174.x. PMID: 16824084.

248- Isma’eel H, Taher A, Shamseddeen W, Khoury M, Gharzuddine W, Arnaout MS, Alam S. SAECG parameters and left ventricular chamber sizes: lesson from anemia conditions in thalassemia major patients. Int J Cardiol. 2006 Nov 18;113(3):E102-4. doi: 10.1016/j.ijcard.2006.06.019. Epub 2006 Aug 2. PMID: 16887209.

249- Cappellini MD, Porter JB, Musallam KM, Kattamis A, Viprakasit V, Galanello R, Taher AT. Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia. Eur J Intern Med. 2016 Mar;28:91-6. doi: 10.1016/j.ejim.2015.10.003. PMID: 26545830.